Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)

International Journal of Hematology

Volumn 92, Issue 5, 2010, Pages 713-724

  Ogura, Michinori ^a,q   Itoh, Kuniaki ^b   Kinoshita, Tomohiro ^c   Fukuda, Haruhiko ^d   Takenaka, Takeaki ^e,r   Ohtsu, Tomoko ^b,s   Kagami, Yoshitoyo ^a,t   Tobinai, Kensei ^e   Okamoto, Masataka ^f   Asaoku, Hideki ^g   Sasaki, Tsuneo ^h   Mikuni, Chikara ^i,u   Hirano, Masami ^f   Chou, Takaaki ^j   Ohnishi, Kazunori ^k   Ohno, Hitoshi ^l,v   Nasu, Kaori ^m,w   Okabe, Kenichi ^n,x   Ikeda, Shuichi ^o,y   Nakamura, Shigeo ^a,c   Hotta, Tomomitsu ^p,z   Shimoyama, Masanori ^e   more..

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^h TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁱ HOKKAIDO CANCER CENTER   (Japan)

^j NIIGATA CANCER CENTER HOSPITAL   (Japan)

^k HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYOTO UNIVERSITY   (Japan)

^m OSAKA RED CROSS HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^o Sasebo Shiritsu Sogo Hospital   (Japan)

^p TOKAI UNIVERSITY   (Japan)

^q NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^r Sapporo Yuushoukan Hospital ^*  (Japan)

^s Bayer Schering Pharma   (Japan)

^t Department of Clinical Laboratory   (Japan)

^u Sapporo Yuushoukan Hospital   (Japan)

^v Takeda General Hospital   (Japan)

^w Nasu Medical Clinic   (Japan)

^x Kihoku Town Hospital   (Japan)

^y Hirado Municipal Hospital   (Japan)

^z NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

ABVd therapy; Chemotherapy; Hodgkin lymphoma; Phase II study

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ABSCESS; ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOXEMIA; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; ENDPOINT DETERMINATION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 78751583938     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0712-8     Document Type: Article

References (34)

1. VT Devita Jr AA Serpick PP Carbone 1970 Combination chemotherapy in the treatment of advanced Hodgkin's disease Ann Intern Med 73 881 895 5525541
2. DL Longo RC Young M Wesley SM Hubbard PL Duffey ES Jaffe, et al. 1986 Twenty years of MOPP therapy for Hodgkin's disease J Clin Oncol 4 1295 1306 1:STN:280:DyaL28zgs12nsA%3D%3D 3528400
3. G Bonadonna R Zucali S Monfardini M De Lena C Uslenghi 1975 Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP Cancer 36 252 259 1:STN:280: DyaE28%2FptVWnug%3D%3D 54209 10.1002/1097-0142(197507)36:1<252::AID- CNCR2820360128>3.0.CO;2-7
4. A Santoro 1979 Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) Cancer Chemother Pharmacol 2 101 105 1:STN:280:DyaL3c7jt1Oksg%3D%3D 93984 10.1007/BF00254081
5. S Viviani A Santoro G Ragni V Bonfante O Bestetti 1985 Bonadonna G: Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD Eur J Cancer Clin Oncol 21 601 605 1:STN:280:DyaL2M3jtVynsA%3D%3D 2408897 10.1016/0277-5379(85)90088-4
6. G Bonadonna A Santoro AM Gianni S Viviani S Siena M Bregni, et al. 1991 Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience Ann Oncol 2 Suppl 1 9 16 1710489
7. GP Canellos JR Anderson KJ Propert N Nissen MR Cooper ES Henderson, et al. 1992 Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med 327 1478 1484 1:STN:280: DyaK3s%2FisVyisQ%3D%3D 1383821 10.1056/NEJM199211193272102
8. Connors JM. Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? Yes. Important Adv Oncol. 1993;189-95.
9. DB Duggan GR Petroni JL Johnson JH Glick RI Fisher JM Connors, et al. 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial J Clin Oncol 21 607 614 1:CAS:528:DC%2BD2cXpsVGrtbg%3D 12586796 10.1200/JCO.2003.12.086
10. Lymphoma Study Group of Japanese Pathologists 2000 The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities Pathol Int 50 696 702 10.1046/j.1440-1827.2000. 01108.x
11. A Jemal R Siegel E Ward Y Hao J Xu T Murray, et al. 2007 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010
12. T Takenaka C Mikuni A Miura T Sasaki H Suzuki T Hotta, et al. 2000 Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adramycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905) Jpn J Clin Oncol 30 146 152 1:STN:280:DC%2BD3c3ls1Cjsg%3D%3D 10798542 10.1093/jjco/hyd036
13. RJ Lukes JJ Butler 1966 The pathology and nomenclature of Hodgkin's disease Cancer Res 26 1063 1083 1:STN:280:DyaF287nt1yjtw%3D%3D 5947336
14. PP Carbone HS Kaplan K Musshoff DW Smithers M Tubiana 1971 Report of the committee on Hodgkin's disease staging classification Cancer Res 31 1860 1861 1:STN:280:DyaE38%2Fks1yitw%3D%3D 5121694
15. TA Lister D Crowther SB Sutcliffe E Glatstein GP Canellos RC Young, et al. 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting J Clin Oncol 7 1630 1636 1:STN:280:DyaK3c%2FjvFCnsA%3D%3D 2809679
16. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden, et al. 1982 Toxicity and response criteria of Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655 1:STN:280:DyaL3s7kvFOgsw%3D%3D 7165009 10.1097/00000421- 198212000-00014
17. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman, et al. 1999 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 3835 3849 1:STN:280:DC%2BD3c%2FksVyltQ%3D%3D 10577857
18. WHO Handbook for Reporting Results of Cancer Treatment, WHO Publication, Geneva 1979.
19. K Tobinai A Kohno Y Shimada T Watanabe T Tamura K Takeyama, et al. 1993 Toxicity grading criteria of the Japan Clinical Oncology Group Jpn J Clin Oncol 23 250 257 1:STN:280:DyaK2c%2Fhslakuw%3D%3D 8411739
20. V Diehl J Franklin M Pfreundschuh B Lathan U Paulus D Hasenclever, et al. 2003 Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med 348 2386 2395 1:CAS:528: DC%2BD3sXksFKgtb8%3D 12802024 10.1056/NEJMoa022473
21. D Hasenclever V Diehl 1998 A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease N Engl J Med 339 1506 1514 1:STN:280:DyaK1M%2FisFenuw%3D%3D 9819449 10.1056/NEJM199811193392104
22. S Viviani G Bonadonna A Santoro V Bonfante M Zanini L Devizzi, et al. 1996 Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results J Clin Oncol 14 1421 1430 1:CAS:528:DyaK28XjtFKis7Y%3D 8622055
23. G Bonadonna P Valagussa A Santoro 1986 Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results Ann Intern Med 104 739 746 1:STN:280:DyaL283htlChsw%3D%3D 2422994
24. R Somers P Carde M Henry-Amar M Tarayre J Thomas A Hagenbeek, et al. 1994 A randomized study in stage IIIB and IV Hodgkin's disease comparing eight cycles of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial J Clin Oncol 12 279 287 1:STN:280:DyaK2c7lslKjtw%3D%3D 7509381
25. A Engert V Diehl J Franklin A Lohri B Dörken WD Ludwig, et al. 2009 Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study J Clin Oncol 27 4548 4554 19704068 10.1200/JCO.2008.19.8820
26. M Federico S Luminari E Iannitto G Polimeno L Marcheselli A Montanini, et al. 2009 ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial J Clin Oncol 27 805 811 19124807 10.1200/JCO.2008.17.0910
27. PJ Hoskin L Lowry A Horwich A Jack B Mead BW Hancock, et al. 2009 Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 J Clin Oncol 27 5390 5396 19738111 10.1200/JCO.2009.23.3239
28. BM Aleman JM Raemaekers U Tirelli R Bortolus MB van't Veer ML Lybeert, et al. 2003 Involved-field radiotherapy for advanced Hodgkin's lymphoma N Engl J Med 348 2396 2406 12802025 10.1056/NEJMoa022628
29. S Laskar T Gupta S Vimal MA Muckaden TK Saikia SK Pai, et al. 2004 Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22 62 68 1:CAS:528:DC%2BD2cXpsVKiurs%3D 14657226 10.1200/JCO.2004.01.021
30. G Bonadonna V Bonfante S Viviani A Di Russo F Villani P Valagussa 2004 ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results J Clin Oncol 22 2835 2841 15199092 10.1200/JCO.2004.12.170
31. RM Meyer MK Gospodarowicz JM Connors RG Pearcey A Bezjak WA Wells, et al. 2005 Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 4634 4642 1:CAS:528:DC%2BD2MXotFarsrY%3D 15837968 10.1200/JCO.2005.09.085
32. Cancer Statistics in Japan-2009. Edited by "Cancer Statistics in Japan" Editorial Board, Foundation for Promotion of Cancer Research, 2009, p4. http://ganjoho.ncc.go.jp/public/statistics/backnumber/1isaao000000068m-att/ fig20.pdf.
33. E Boleti GM Mead 2007 ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors Ann Oncol 18 376 380 1:STN:280:DC%2BD2s%2FotlaktQ%3D%3D 17071938 10.1093/annonc/mdl397
34. E Brusamolino AP Anselmo C Klersy M Santoro E Orlandi G Pagnucco, et al. 1998 The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs compared to chemotherapy alone and correlates with extension of radiotherapy and type and duration of chemotherapy: a case control study Haematologica 83 812 823 1:STN:280: DyaK1M%2FktlSiuw%3D%3D 9825578